Condition: Gallbladder Neoplasm Malignant Primary
Intervention: Procedure: Radical surgery
Sponsor: Emilio Ramos
Not yet recruiting
Feeds
10095 items (10095 unread) in 74 feeds
Acinar Cell Carcinoma
(96 unread)
Acinic Cell Carcinoma
(21 unread)
Adenoid Cystic Carcinoma
(223 unread)
Adrenal Gland Cancer
(899 unread)
Ampulla Of Vater
(75 unread)
Anal Cancer
(911 unread)
Angiosarcoma
(174 unread)
Appendix Cancer
(147 unread)
Bile Duct Cancer
(1427 unread)
Brain and CNS
(1389 unread)
Carcinoid
(311 unread)
Endocrine/Neuroendocrine
(968 unread)
Gall Bladder Cancer
(431 unread)
Hemangioendothelioma
(248 unread)
Hepatoblastoma
(123 unread)
Pancreas
(139 unread)
Phyllodes
(95 unread)
PMP and Mucinous Tumors
(62 unread)
Rhabdomyosarcoma
(337 unread)
Sarcoma
(2019 unread)
Trials - Gall Bladder Cancer (8 unread)
-
Validation of a Score That Predicts Residual Disease in Incidental Gallbladder Cancer
Posted: March 25th, 2020, 2:00pm GMT
-
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
Posted: March 13th, 2020, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Gallbladder Cancer; Cholangiocarcinoma
Interventions: Drug: Durvalumab + Gem/Cis; Drug: Gem/Cis
Sponsors: Asan Medical Center; Samsung Medical Center
Not yet recruiting -
The Incidence of Gallstones After Gastric Cancer Surgery
Posted: January 31st, 2020, 3:00pm GMT
Conditions: Gallstones; Gastric Cancer
Intervention: Procedure: Resection
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Not yet recruiting -
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Posted: December 18th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: University of Michigan Rogel Cancer Center
Not yet recruiting -
Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma
Posted: August 16th, 2019, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Combination Product: Combination of Lonsurf® and Campto®
Sponsors: RWTH Aachen University; Servier
Not yet recruiting -
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Posted: June 27th, 2019, 2:00pm GMT
Conditions: Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Cell Lymphoma, Nasal
Intervention: Biological: STI-3031
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting -
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Posted: December 31st, 2018, 3:00pm GMT
Condition: Biliary Tract Cancer
Intervention: Drug: telotristat ethyl
Sponsor: Lexicon Pharmaceuticals
Recruiting -
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Posted: March 11th, 2011, 3:00pm GMT
Conditions: Non-GI Cancers; Cancer of Gastrointestinal Tract; Gastrointestinal Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting